Systems and methods for disease control and management

Information

  • Patent Grant
  • 10818389
  • Patent Number
    10,818,389
  • Date Filed
    Monday, November 12, 2018
    6 years ago
  • Date Issued
    Tuesday, October 27, 2020
    4 years ago
Abstract
Methods, computer-readable media, and systems for providing disease management. In one implementation, a system develops a treatment recommendation for a patient based on patient data. The system may receive patient data, execute a basic model of the physiological system of the patient to generate a modified model for the patient based on the patient data, perform a statistical analysis of the patient data to detect data excursions of the parameter values; use the modified model to determine factors causing the data excursions; and use the model to develop a treatment recommendation to ameliorate negative effects of the disease.
Description
TECHNICAL FIELD

The present invention generally relates to the field of disease management. More particularly, and without limitations, the invention relates to systems and methods for disease management by providing treatment recommendations and information based on relevant data collected about a patient.


BACKGROUND

Generally speaking, disease management refers to a wide range of activities that may affect a patient's health status. These activities include programs to improve a patient's compliance with their treatment regimen, and helping the patient adjust their regimen according to evidence-based treatment guidelines. The goal of these programs is to attempt to maintain or improve the patient's health status and quality of life, and to reduce the total costs of health care.


One approach is to identify and provide a variety of appropriate services to patients that are suitable for a certain program. Examples of such services include periodic phone calls to a patient to monitor the status of the patient, personalized goal-oriented feedback on the patient's self care, access to nurse call centers, and educational materials. Some of these programs attempt to modify services based on data obtained from the patient's self reports and administrative claims. These programs attempt to help patients identify regimens, manage their symptoms, self-monitor their conditions, and comply with their treatment. The drawbacks of this type of approach include the enormous resources necessary to provide these human-based services, and the lack of timely, appropriate, and accurate patient data to provide appropriate services. For example, a single case manager can only assist a limited number of patients. As a result, such a case manager may, for example, be able to contact a patient only once a month and may be forced to rely on out-dated data for the patient.


An alternative approach for disease management is to use a system that provides corrective action to a patient based on limited information provided by the patient. For example, a diabetes patient can provide their current glucose value using an electronic patient-operated apparatus, and the system can recommend a corrective action to the patient based on the application of formulas well known in the art. A corrective action can be either administration of an extra insulin dose or consumption of carbohydrates. A drawback of this approach is that it fails to provide customized disease management for each individual patient. Similarly, the formulas that can be applied for any patient part of the general population do not take into account the complete dynamics of a particulars patient's disease and the corrective actions advised to a patient are limited. As a result, a patient is denied the optimal treatment recommendations that can only be targeted for a particular patient. Finally, the success of the system is wholly dependent on a proactive and conscientious patient.


In view of the foregoing, there is a need for an improved solution for disease management. In particular, there is a need for systems and methods for effective disease management that can develop recommendations for a patient based on the particular patient's data.


SUMMARY

The present invention provides methods, computer-readable media, and systems for providing disease management. This is achieved by providing treatment recommendations targeted for a particular patient based on the patient's data.


In one exemplary embodiment, a system is provided including, for example, an input device for receiving patient data; a transmitter for transmitting the received patient data from the input device; and a disease management server. The disease management server may include a receiver for receiving the transmitted patient data, a processor for developing a treatment recommendation, and an output device for outputting the treatment recommendation. The processor may develop treatment recommendations by executing a basic model of the physiological system of the patient to generate a modified model for the patient based on the patient data, performing a statistical analysis of the patient data to detect data excursions of the parameter values, using the modified model to determine factors causing the data excursions, and using the model to develop a treatment recommendation to ameliorate negative effects of the disease. The patient data may include but is not limited to the following parameters: patient carbohydrate intake, patient medication doses, blood glucose level, activity of the patient, and the corresponding time and optional context for the data.


The processor in the disease management server of the exemplary system may generate a plurality of treatment recommendations, including, for example, recommendations for dosing and timing of medication, and for patient dietary behavior. Executing the model comprises applying an algorithm to the patient data in a current state in conjunction with auxiliary patient data including, for example, patient blood lipid level, blood pressure, age, gender, height and weight, and race. The processor may be further configured to develop recommendations for collection of the patient data to improve the model, wherein the collection recommendations comprise recommendations for timing of blood glucose measurement. The processor may be further configured to perform statistical analysis employing a statistical design of experiments methodology and multivariate analyses to identify the factors causing the data excursions.


In another embodiment, the treatment recommendations may be developed at predetermined intervals, which may be determined based on a most-recent patient data collection time. The treatment recommendations may include a recommended time and dose of medication, including recommended combinations of available medications. The treatment recommendations may also include a recommended time and amount of carbohydrate intake.


In another alternate embodiment, the input device may be a patient-interactive interface operated by the patient. The system may include a portable device configured to operate the patient-interactive interface and the transmitter, wherein the transmitter transmits signals over a wireless communication to the disease management server. The system may also include a physician interface operable to receive information about the patient from the disease management server.


In another alternate embodiment, the patient data may be calibrated at a plurality of reading points to provide more information on pharmacokinetic/pharmacodynamic interactions of the patient.


In another alternate embodiment, generating the modified model may include utilizing equations that simulate interaction of primary factors effecting rate of change of the blood glucose of the patient, wherein the primary factors are calculated based on the patient data. The primary factors may include rate of digestion of the patient carbohydrate intake, cellular uptake of blood glucose by the patient, and impact of glucose inventory in liver, skeletal muscle, and fat tissues of the patient. The equation for the cellular uptake is a function of the blood glucose level, level of insulin acting as a catalyst, resistance factors, and digestive-activated hormones, and wherein the level of insulin is calculated based on the patient medication doses, patient pancreatic production, and insulin kinetics.


It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this disclosure, illustrate embodiments and aspects of the present invention. In the drawings:



FIG. 1 illustrates an exemplary system, consistent with an embodiment of the invention.



FIG. 2 is a flowchart of an exemplary method, consistent with an embodiment of the present invention;



FIG. 3 is a flowchart of an exemplary method for collecting patient data, consistent with an embodiment of the present invention;



FIG. 4 depicts an example of a disease managements server developing treatment recommendations, consistent with an embodiment of the present invention;



FIG. 5 is an exemplary diagram showing a generation of a modified model for a patient, consistent with an embodiment of the present invention;



FIG. 6 is an exemplary diagram showing a determination of the insulin of a patient, consistent with an embodiment of the present invention;





DESCRIPTION OF THE EMBODIMENTS

The following detailed description refers to the accompanying drawings. Wherever possible, the same reference numbers are used in the drawings and the following description to refer to the same or similar parts. While several exemplary embodiments and features of the invention are described herein, modifications, adaptations and other implementations are possible, without departing from the spirit and scope of the invention. For example, substitutions, additions, or modifications may be made to the components illustrated in the drawings, and the exemplary methods described herein may be modified by substituting, reordering, or adding steps to the disclosed methods. Accordingly, the following detailed description does not limit the invention. Instead, the proper scope of the invention is defined by the appended claims.



FIG. 1 illustrates components of an exemplary system 100, consistent with an embodiment of the present invention. The two main components of the system are an input device 110 and a disease management server 130. A transmitter 120 may be a separate component or part of the input device. Transmitter 120 may include a modem to transmit information collected by input device 110 to disease management server 130. Transmitter 120 may also be used to receive information from disease management server 130 to provide to the user through the input device 110. For example, disease management server 130 may send information regarding what data it needs input device 100 collect from the patient.


Input device 110 and the transmitter 120 may be part of a single computer system. Alternatively, the transmitter may be on an intermediary computer system between the input device 110 and the disease management server 130. The transmitter 120 may serve as the intermediary for communication between the input device 110 and the disease management server. The components 110, 120, 130 may communicate with each over a communication medium 125. The communication medium may be any desired type of communication channel, including (but not limited to) the public switched telephone network (VSTN), cellular channel, other wireless channel, internal computer bus, intranet, Internet, etc.


The input device 110 may be used to collect variety of patient data in a variety of ways. The input device 110 may be connected to one or more biometric measurement devices to collect biometric data. The biometric measurement devices may be implanted in the patient, connected to the patient, and/or completely external. A biometric measurement device may be part of or connected to the input device 110, or it may be a stand-alone device. A stand-alone biometric measurement device may communicate wirelessly with the input device 110, Examples of biometric measurement devices include, but are not limited to, scales, external blood pressure monitors, cardiac data sensors, implantable blood glucose sensors for continuous sensing, external blood glucose monitors, etc.


The input device 110 may also receive information from devices for administering medication. For example, the input device 110 may be connected to an insulin-delivery device. The input device 110 may receive information detailing the insulin doses a patient has taken from the insulin-delivery device and the times of dose administration.


The input device 110 may also receive information from other ancillary devices to collect a variety of information about the patient's behavior and status. For example, the input device 110 may be connected to a pedometer worn by the patient or exercise equipment used by the patient to track the physical activity of the patient. The input device 110 may be connected to a GPS system to track the movement and location of the patient. The input device may also be connected to a device that keeps track of a patient's dietary behavior.


The input device 110 may also receive information by having the patient enter particular information. The disease management server 130 may send request for particular information to be entered by the patient using the input device 110. The input device 110 may prompt the user to enter the particular information. The request sent by the disease management server 130 may be in the form of surveys designed to collect particular information. The surveys may be targeted to collect information about a patient's dietary behavior (e.g., carbohydrate intake, portion control), self-monitoring of blood glucose, medication doses, physical activity, psychological status, alcohol intake, smoking activity, and any other information that might effect the patient's well being. The input device 110 may prompt the patient to enter information by displaying the survey and receiving the patient's responses to the questions posed in the survey. The scripts may also be designed to educate the patient or to promote positive behavior/behavior modification by the patient.


The transmitter 120 may send the patient data collected by the input device 110 to the disease management server 130 immediately after the data is entered into the input device 110 by the patient.


As shown in FIG. 1, disease management server 130 may include a receiver 131, a processor 132, and an output device 133. The receiver 131 may receive patient data from the transmitter 120. The processor 132 may execute a program for generating/maintaining a modified model for a patient and developing treatment recommendations for the patient using the model based on the patient data. The output device 133 may output information to either the patient, a third party health care provider, or a remote device based on the treatment recommendations developed by the processor 132.


The processor 132 may generate a modified model for the patient based on the patient data the disease management server 130 receives through the receiver 131. The modified model may be used to estimate impact of a change in the patient's regimen (e.g., medication, food intake, physical activity) on the physiological system of the patient. The processor may generate a modified model for the patient by executing a basic model. A basic model models a physiological system of a patient based on established knowledge of disease dynamics and factors. The patient data is used to generate the modified model for a particular patient. The modified model can provide guidance to improve the patient's regimen and to gain a better understanding of how a particular patient is being affected by a disease dynamic. The use of patient data over an extended period of time allows the modification and improvements of the modified model as more data is collected for a particular patient. The modified model may also be used even when limited/incomplete patient data is received.


After the generation of a modified model, the processor 132 may perform a statistical analysis of patient data to detect data excursions. A data excursion is an event in which a value of a parameter (e.g., blood glucose level) is outside the normal/expected range for the parameter. The processor 132 may use the modified model it generated to determine the factors causing the data excursions and the effects of such data excursions. The modified model may then be used to develop a plurality of treatment recommendations to ameliorate negative effects of the disease. The output device 133 within the disease management server 130 may output information based on the treatment recommendations to the patient, a device relate to the patient, or a third party.



FIG. 2 is a flowchart of an exemplary method 200, consistent with an embodiment of the present invention. Method 200 may be executed on a system illustrated in FIG. 1. According to the method, at step 201, the input device 110 may collect patient data. At step 202, the transmitter 120 may transmit the patient data to the disease management server 130. At step 203, the disease management server 130 may generate a modified model for the patient. At step 204 the disease management server 130 may develop treatment recommendations for the patient using the modified model generated at step 203. At step 205 the disease management server 130 may deploy treatment recommendations developed at step 204, by using the output device 133.



FIG. 3 is a flowchart of another exemplary method 300, consistent with an embodiment of the present invention. Method 300 depicts an example of an input device 110 receiving patient data. Steps 301, 303, 304, 305 of this method may be performed in no particular order. Steps 301, 303, 304, 305 present a limited set of examples of the different patient data that can be collected and how it may be collected by an input device 110.


At step 301, the input device 110 may receive data collected by one or more biometric measurement devices. The input device 110 may receive the data collected by one or more biometric measurement devices every time a measurement occurs by the biometric measurement device, at a certain predetermined interval, or when the input device is prompted to collect the biometric measurement data. Alternatively, as discussed above, at step 301, the biometric measurement data may be entered by the patient into the input device 110.


At step 302, the input device may prompt the user to enter specific information pertaining to factors that can effect the well being of the patient. The patient may be prompted to enter such information by being asked a series of questions. The patient may receive reminders through the input device to enter certain type of information at a certain time. Step 302 may repeat several times to collect different types of data from the patient at steps 301, 303, 304, 305.


At step 303, the input device 110 may receive information about the patient's dietary behavior. This information may be simply entered by the patient on a regular basis using the input device. The patient may use a remote workstation to enter the information and have it transferred to the input device. The information may be entered in response to the prompt(s) at step 302. The information may be received from a device that can track a patient's dietary behavior. An example of such a device is a food/drink caloric intake calculator. The calculator may be implemented, for example, on a cell phone, and a patient may enter information regarding his/her dietary behavior into the cell phone. Alternatively, the calculator may be part of the input device. The information may also be received by the input device 110 from a restaurant where the patient eats. Another example is a camera-based food calculator. The input device 110 may be able to receive pictures of food eaten by the patient. Image recognition techniques may later be used to identify the food consumed by the patient, and determine the carbohydrate intake of the patient for example.


At step 304, the input device 110 may receive information about what medications the patient is taking, at what doses, and at what times. The patient may simply enter the information to be received by the input device independently, or the patient may enter the information in response to a prompt at step 302. The input device 110 may also be connected to other devices, and may receive information regarding the patient's medication intake from the other devices.


At step 305, the input device 110 may receive any other pertinent information from the patient that may assist successful disease management. This information may be received directly from the patient, a health care provider, a monitoring device, a third party, etc, A person can be prompted by the input device 110 to enter the information. Examples of information that may be collected may relate to the patient's exercise, smoking, alcohol intake, etc.


The input device 110 may also receive information from the patient at steps 301, 303, 304, and 305 regarding patients attitude towards modifying behavior that affects the respective data received at each step.



FIG. 4 is a flowchart of another exemplary method 400, consistent with an embodiment of the present invention. Method 400 depicts an example of a disease management server 130 generating treatment recommendations for a patient. At step 401, a receiver 131 of the disease management server 130 receives patient data from a transmitter 120. The patent data is collected by input device 110 (see FIG. 3) and transmitted by transmitter 120 from the input device 110 to the disease management server 130. Steps 402, 403, 404, 405 may be performed by a processor 132 in the disease management server.


At step 402, the disease management server 130 uses the patient data to generate a modified model of the patient's physiological system. The modified model may be used to estimate the impact of a change of a certain factor (data) on the patient (other data). The modified model represents the effects of a change in different data on the particular patient's physiological system, and in turn how the physiological system of the patient effects the data. The modified model may be a previously generated modified model updated based on new patient data. The model is generated by executing a basic model based on the patient data (402). The basic model represents the minimal assumptions and parameters of a person's physiological system and the correlation of certain factors. How the factors interact and correlate is different for different patients. The patient data is used to adjust the basic model and generate a modified model for a particular patient. The more patient data is collected over time, the more accurate the modified model is for the particular patient. In addition, the collection of data from multiple patients may be used to improve the basic model.


At step 403, the disease management server 130 performs a statistical analysis to detect data excursions in the patient data. A data excursion may be indicated when certain data collected at a certain time is outside the normal range that can be expected for that data for the particular patient. For example, a data excursion may be a blood glucose measurement that is outside the normal blood glucose range for the particular patient.


At step 404, the disease management server 130 uses the modified model generated at step 402 to determine the factors causing the data excursions detected at step 403. For example, the disease management server 130 may determine if a change in amount of timing of medication or food intake of the patient caused the data excursion of blood glucose measurement.


At step 405, the disease management server 130 may develop treatment recommendations to ameliorate negative effects of the patient's disease. The disease management server 130 may use the modified model to determine the treatment recommendations which are optimal for the patient. For example, if a data excursion caused a negative effect on the patient, a treatment recommendation may be developed to prevent such a data excursion in the future. Examples of treatment recommendations may include adjusting food or medication intake, adjusting how and what data is collected, advising the patient to modify certain behaviors, providing educational materials to the patient, alerting the patient's health care provider, etc.


At step 406, the output device 133 of disease management server 130 may output the treatment recommendations developed at step 405. The treatment recommendations are transmitted to the appropriate party or device. For example, a treatment recommendation to increase the patient's insulin dose can be transmitted directly to the insulin-delivery device (pump). If, for example, the treatment recommendation is to collect certain additional data about the patient to provide optimal treatment recommendations in the future, a script can be transmitted to the patient through the input device 110 to collect the additional data at certain times.



FIG. 5 is an exemplary diagram showing a generation of a modified model for a patient, consistent with an embodiment of the present invention. The modified model is generated by the basic model. The diagram, in effect, is representing the basic model. The model in this embodiment focuses on the primary factors that impact the daily blood glucose (BG) of a patient: carbohydrate intake, insulin level of the patient, and glucose inventory of the patient. The model inherently includes within these primary factors the complex interactions of the hormonal-signaling network that supports the endocrine processes. First, it is necessary to determine the carbohydrate intake 501, insulin level 503, and glucose inventory 505 of the patient to generate the model. The patient data is used to determine the respective primary factors. The carbohydrate intake is determined based on the amount of carbohydrates ingested by the patient that become the primary source of blood glucose for the patient (501). The insulin level of the patient is determined on a variety of factors including dosing, pancreatic production, and kinetics (505, see FIG. 6 for further detail). The glucose inventory is determined based on the glucose stored in the liver, skeletal muscle, and fat tissues of the patient (506).


After determining the carbohydrate intake of the patient, an impact of the carbohydrate intake (carbs) on concentration of the blood glucose may be modeled (502). This may be modeled based on the following equation for instantaneous blood glucose concentration:









d


[
BG
]


dt

=

β



d


[

carbs
,
BG
,
incretins

]


dt



,





wherein [BG] may be blood glucose (BG) concentration, [carbs] may be represented as a first order kinetics function of time (t), β may be for example about 5 BG units/carbohydrate unit, and incretins are the digestive-activated hormones of the patient.


The impact of insulin on transfer of blood glucose into patient's cells (504) is accounted for in the modified model. Insulin is accounted for as a catalyst, not as a compound that forms with blood glucose. The instantaneous rate decrease of blood glucose concentration from instantaneous insulin concentration in blood may be modeled based on the following equation: wherein








-


d


[
BG
]


dt


=


α


(
t
)


×


[
BG
]



[
insulin
]




,





[insulin] may be the instantaneous insulin concentration in blood, a includes resistance impact of diabetes and is about 0.3 if rate is −50 BG units/insulin unit above BG of 140, and α(t) includes diurnal variations. Alternatively, α(t) may be approximated without any time dependence, using the 24 hour mean.


Finally, it is necessary to account for the impact of the glucose inventory (IG) on the blood glucose (BG) (506), where the glucose inventory absorbs blood glucose on storage and release blood glucose on retrieval (mass action kinetics). This may be modeled based on the following equation:









d


[
BG
]


dt

=

-


d


[
IG
]


dt



,





where









d


[
IG
]


dt

=

-

γ


(


[
IG
]

+


{


-

[
BG
]


-

[
IG
]


}


{

1
+

exp


(

ω


{

τ
-

α


[
insulin
]



}


)



}



)




,





wherein τ is the threshold; if resistant insulin is greater then the threshold, then blood glucose decreases by going into liver and fat as glucose storage (IG) and is not released through the liver. And wherein γ relates concentration of glucose to changes in IG. The IG functionality may be modeled by other similar forms at the conceptual level since the phenomenological description is incomplete.


The total change in blood glucose over a time interval (508) may be modeled based on the sum of the three factors 502, 504, 506 described above. The complete basic model may be based on the following equation (509):









d
dt



BG


(
t
)



=

[


[


β


(


d
dt



carbs


(
t
)



)


-

α
·

BG


(
t
)


·

insulin


(
t
)




]

-


d
dt



IG


(
t
)



+
errors

]


,





where the storage or release of blood glucose as mediated by resistant insulin may be expressed in the following equation:









d
dt



IG


(
t
)



=

-

γ


[


IG


(
t
)


+


(


-

BG


(
t
)



-

IG


(
t
)



)


[

1
+

exp


[

W
·

(

τ
-

B
·

insulin


(
t
)




]


]






]




,





wherein W is the switching rate (i.e., the rate that IG switches from intake mode to output mode of BG). Errors may account for any additional or unknown factors besides the primary factors (507). Statistical methods may be used to estimate model parameters and their expected variations for a patient.


The model can then be used to determine factors causing the data excursions 404. The relative contributions of the primary factors may vary over the 24 hour day, especially adjacent to meals and fasting events. For example, the fasting segments of the BG profile between meals would see lithe impact from the carbohydrates (502), and, if in addition, insulin levels are near their norm's as defined by its storage threshold, then insulin (504) becomes the dominant effect. Hence, this allows an estimation of the a parameter and the insulin profile of the patient based on the model. The dosing profile is known (503), and comparison with the estimated profile provides information on pancreatic activity. Under these conditions, one can also test if a changes among different fasting events. The testing can be accomplished through a treatment recommendation. The model provide a guide for timely regimen optimization for the particular patient. The optimization is based on a minimal-assumption model (MAM) that fits the major features in the data patterns of the patient. The MAM for BG data patterns may be expressed, for example, as follows: BG=MAM(t, injections, orals, digestion, diurnals, activity, liver processes, immune reaction, beta islets)+error.


Given α, one can estimate inventory parameters from the segments of the model capturing fasting events at non-normal levels of insulin. With these two sources established, one can now estimate the impact of carbohydrates during meals, since carbohydrates kinetics are known. Similarly, the MAM may be used to determine the effect on the patient's BG of changing other factors (ex. medications). A key feature of MAM is that it can model answers to “what if” questions for each individual patient given any scenario of lifestyle and treatment regimen/conditions over any interval of time both retrospectively and prospectively.



FIG. 6 is a diagram showing a determination of the insulin of a patient (503), consistent with an embodiment of the present invention. The insulin of a patient may be calculated 604 based on the insulin from the medication received by the patient 601, the insulin produced by the patient's pancreatic beta cells 602, and mass action kinetics of insulin 603. The effect of mass action kinetics on insulin may be accounted for, based on the following formula: insulin(t)=D (dbeta [0.3 (t−0.5), 2.1, 7]+E), wherein D is the units of insulin dose received by the patient, and wherein E is the approximate equilibrium level of 24 hour SA insulin. Optionally, one may use kinetics models to create the insulin dosing profiles. The insulin profile may take into account the difference between long-acting and short-acting kinetics that vary based on the source of the insulin.


The foregoing description has been presented for purposes of illustration. It is not exhaustive and does not limit the invention to the precise forms or embodiments disclosed. Modifications and adaptations of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the disclosed embodiments of the invention. For example, the described implementations include software, but systems and methods consistent with the present invention may be implemented as a combination of hardware and software or in hardware alone. Examples of hardware include computing or processing systems, including personal computers, servers, laptops, mainframes, micro-processors and the like, Additionally, although aspects of the invention are described for being stored in memory, one skilled in the art will appreciate that these aspects can also be stored on other types of computer-readable media, such as secondary storage devices, for example, hard disks, floppy disks, or CD-ROM, the Internet or other propagation medium, or other forms of RAM or ROM.


Computer programs based on the written description and methods of this invention are within the skill of an experienced developer. The various programs or program modules can be created using any of the techniques known to one skilled in the art or can be designed in connection with existing software. For example, program sections or program modules can be designed in or by means of Java, C++, HTML, XML, or HTML with included Java applets. One or more of such software sections or modules can be integrated into a computer system or existing e-mail or browser software.


Moreover, while illustrative embodiments of the invention have been described herein, the scope of the invention includes any and all embodiments having equivalent elements, modifications, omissions, combinations (e.g., of aspects across various embodiments), adaptations and/or alterations as would be appreciated by those in the art based on the present disclosure. The limitations in the claims are to be interpreted broadly based on the language employed in the claims and not limited to examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive. Further, the steps of the disclosed methods may be modified in any manner, including by reordering steps and/or inserting or deleting steps, without departing from the principles of the invention. It is intended, therefore, that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims and their full scope of equivalents.

Claims
  • 1. A system for management of a user having a glucose condition, comprising: an insulin delivery device configured to execute instructions, as part of a treatment recommendation, to deliver insulin, the insulin delivery device having a pump and a transmitter to output at least insulin intake data, including a dosage and a time of insulin intake, and to receive instructions; anda disease management server, comprising: a receiver for wirelessly receiving user data, including at least the insulin intake data, transmitted from the insulin delivery device, glucose data, including glucose measurements and timing of measurement of glucose, from a glucose measuring device, and physical activity data from a pedometer worn by the user or exercise equipment used by the user;one or more processors configured to apply an algorithm to the received user data, wherein executing the algorithm includes: executing a basic model of a physiological system generic to any user, the basic model being based on a plurality of parameters of the physiological system, the plurality of parameters including an insulin intake, a time of insulin intake, a glucose level, a time of measurement of glucose level, physical activity of the user, and a time of physical activity of the user;adjusting the basic model based on the received user data to generate a modified model specific to a physiological system of the user, wherein generating the modified model includes determining a rate of change in glucose level of the user over a time interval based on glucose inventory;performing a statistical analysis of the user data to detect data excursions of values of one or more parameters, of the plurality of parameters, of the physiological system of the user, wherein a data excursion is a value of a parameter that is outside an expected range of values of the parameter;outputting an alert to a provider associated with the user when a data excursion is detected;executing the modified model to determine factors causing the data excursions of the values of the one or more parameters;generating, using the modified model and the determined factors, one or more instructions, as part of the treatment recommendation, relating to adjusting one or both of a time and a dose of insulin;wirelessly receiving additional user data, the additional user data including at least glucose measurements from the glucose measuring device; andautomatically updating the modified model based on the received additional user data; andan output device for outputting the treatment recommendation, including the one more instructions relating to adjusting the one or both of the time and the dose of insulin, to at least the insulin delivery device,wherein, when the insulin delivery device receives the one more instructions relating to adjusting the one or both of the time and the dose of insulin, the insulin delivery device delivers a dose of insulin at a time based on the one or more instructions relating to adjusting the one or both of the time and the dose of insulin.
  • 2. The system of claim 1, wherein the user data further includes at least one of: (a) user carbohydrate intake, or(b) corresponding time for the user carbohydrate intake.
  • 3. The system of claim 1, wherein the executing the basic model comprises applying an algorithm to the user data in a current state in conjunction with auxiliary user data comprising at least one of a user blood lipid level, a user blood pressure, a user age, a user gender, a user height and weight, or a user race.
  • 4. The system of claim 1, wherein the one or more processors are further configured to develop instructions for collection of the user data to improve the basic model, wherein the instructions for collection comprise an instruction for the glucose measuring device to change a timing of glucose measurement.
  • 5. The system of claim 1, wherein the using the modified model to develop the one more instructions, as part of the treatment recommendation, comprises using the modified model to develop a plurality of treatment recommendations at predetermined intervals.
  • 6. The system of claim 5, wherein the intervals are determined based on a most-recent user data collection time.
  • 7. The system of claim 1, wherein the one or more processors are further configured to perform the statistical analysis employing a statistical design of experiments methodology to identify the factors causing the data excursions.
  • 8. The system of claim 1, wherein the one or more instructions further relate to changing recommended combinations of available medications.
  • 9. The system of claim 1, wherein the generating the modified model comprises utilizing equations that simulate interaction of primary factors affecting the rate of change in glucose level of the user, wherein the primary factors are calculated based on the user data, and the primary factors comprise at least one of a rate of digestion of user carbohydrate intake, cellular uptake of glucose by the user, and impact of glucose inventory in liver, skeletal muscle, or fat tissues of the user.
  • 10. The system of claim 9, wherein an equation for cellular uptake of glucose by the user is a function of at least one of the glucose level, level of insulin acting as a catalyst, resistance factors, or digestive-activated hormones, and wherein the level of insulin is calculated based on at least one of user medication doses, user pancreatic production, or insulin kinetics.
  • 11. A system for management of a user having a glucose condition, comprising: an insulin delivery device configured to operate a user-interactive interface and to execute instructions, as a part of a treatment recommendation, to deliver insulin, the insulin delivery device having a transmitter to output at least insulin intake data, including a dose and a time of insulin intake, and to receive instructions; anda disease management server, comprising: a receiver for wirelessly receiving user data, including at least the insulin intake data, transmitted from the insulin delivery device, and glucose data, including glucose measurements and times of measurement of glucose, from a glucose measuring device, wherein the glucose measurements are received at predetermined intervals;one or more processors configured to execute an algorithm to the received user data, wherein executing the algorithm includes: executing a basic model of a physiological system generic to any user, the basic model being based on a plurality of parameters of the physiological system, the plurality of parameters including an insulin intake, a time of insulin intake, a glucose level, a time of measurement of glucose level, activity of the user, and a time of activity of the user, wherein executing the basic model comprises applying an algorithm to the user data in a current state in conjunction with auxiliary user data comprising each of user blood lipid level, blood pressure, age, gender, height and weight, and race;adjusting the basic model based on the received user data to generate a modified model specific to a physiological system of the user, wherein generating the modified model includes determining a rate of change in glucose level of the user over a time interval based on glucose inventory, and utilizing equations that simulate interaction of primary factors affecting the rate of change in glucose level of the user, wherein the primary factors are calculated based on the user data, and the primary factors comprise a rate of digestion of user carbohydrate intake, cellular uptake of glucose by the user, and impact of glucose inventory in liver, skeletal muscle, and fat tissues of the user, an equation for cellular uptake of glucose by the user is a function of at least one of the glucose level, level of insulin acting as a catalyst, resistance factors, or digestive-activated hormones, and wherein the level of insulin is calculated based on each of user medication doses, user pancreatic production, and insulin kinetics;performing a statistical analysis of the user data to detect data excursions of values of one or more parameters, of the plurality of parameters, of the physiological system of the user, wherein a data excursion is a value of a parameter that is outside an expected range of values of the parameter;outputting an alert to a health care provider associated with the user when a data excursion is detected;executing the modified model to determine factors causing the data excursions of the values of the one or more parameters;generating, using the modified model and the determined factors, one or more instructions, as part of the treatment recommendation, relating to adjusting one or more of a time and a dose of insulin and a combination of medication, wherein using the modified model to develop the one or more instructions, as part of the treatment recommendation, comprises using the modified model to develop a plurality of treatment recommendations at predetermined intervals, wherein the predetermined intervals are based on a most-recent user data collection time;wirelessly receiving additional user data, the additional user data including at least glucose measurements from the glucose measuring device;automatically updating the modified model based on the received additional user data;developing instructions for collection of the user data to improve the basic model, wherein the instructions for collection comprise an instruction for the glucose measuring device to change a timing of glucose measurement; andperforming the statistical analysis employing a statistical design of experiments methodology to identify the factors causing the data excursions;an output device for outputting the treatment recommendation, including the one or more instructions relating to adjusting the one or more of the time and the dose of the insulin, to the insulin delivery device, wherein, when the insulin delivery device receives the one or more instructions relating to adjusting the one or both of the time and the dose of the insulin, the insulin delivery device delivers a dose of insulin at a time based on the one or more instructions relating to adjusting the one or both of the time and the dose of the insulin;anda health care provider interface operable to receive information about the user, including the alert to the health care provider and the treatment recommendation, from the disease management server.
  • 12. The system of claim 11, wherein the glucose condition is diabetes.
  • 13. The system of claim 11, wherein the insulin delivery device includes a pump.
  • 14. The system of claim 1, wherein the treatment recommendation includes at least one instruction for the user to provide the additional user data.
  • 15. A system for management of a user having a glucose condition, comprising: an insulin delivery device configured to execute instructions, as part of a treatment recommendation, to deliver insulin, the insulin delivery device having a pump and a transmitter to output at least insulin intake data, including a dose and a time of insulin intake, and to receive instructions; anda disease management server, comprising: a receiver for wirelessly receiving user data, including at least the insulin intake data, transmitted from the insulin delivery device, and glucose data, including glucose measurements and timing of measurement of glucose level, from a glucose measuring device;one or more processors configured to execute an algorithm to the received user data, wherein executing the algorithm includes: executing a basic model of a physiological system generic to any user, the basic model being based on a plurality of parameters of the physiological system, the plurality of parameters including an insulin intake, a time of insulin intake, a glucose level, and a time of measurement of glucose level, wherein executing the basic model comprises applying an algorithm to the user data in a current state in conjunction with auxiliary user data comprising at least one of a user blood lipid level, a user blood pressure, a user age, a user gender, a user height and weight, or a user race;adjusting the basic model based on the received user data to generate a modified model specific to a physiological system of the user, wherein generating the modified model includes determining a rate of change in glucose level of the user over a time interval based on received glucose measurements and times of measurement of glucose level of the user, and utilizing equations that simulate interaction of primary factors affecting the rate of change in glucose level of the user, wherein the primary factors are calculated based on the user data, and the primary factors comprise at least one of a rate of digestion of user carbohydrate intake, cellular uptake of glucose by the user, and impact of glucose inventory in liver, skeletal muscle, or fat tissues of the user;performing a statistical analysis of the user data to detect data excursions of values of one or more parameters, of the plurality of parameters, of the physiological system of the user, wherein a data excursion is a value of a parameter that is outside an expected range of values of the parameter;outputting an alert to a provider associated with the user when a data excursion is detected;executing the modified model to determine factors causing the data excursions of the values of the one or more parameters;generating, using the modified model and the determined factors, instructions, as part of the treatment recommendation, relating to adjusting one or more of a time and a dose of insulin, and a time of measurement of glucose level, wherein using the modified model to develop the instructions, as part of the treatment recommendation, comprises using the modified model to develop a plurality of treatment recommendations at predetermined intervals, the predetermined intervals being based on a most-recent user data collection time;wirelessly receiving additional user data, the additional user data including at least glucose measurements from the glucose measuring device; andautomatically updating the modified model based on the received additional user data; andan output device for outputting the treatment recommendation, including the instructions, to the insulin delivery device and the glucose measuring device,wherein, when the insulin delivery device receives the instructions relating to adjusting the one or more of the time and the dose of the insulin, the insulin delivery device delivers a dose of insulin at a time based on the instructions relating to adjusting the one or both of the time and the dose of the insulin, and, when the glucose measuring device receives the instructions relating to adjusting the time of measurement of the glucose level, the glucose measuring device adjusts the time of measurement of the glucose level based on the instructions relating adjusting the time of measurement of the glucose level.
RELATED APPLICATION(S)

This application is a continuation of U.S. patent application Ser. No. 15/670,551, filed on Aug. 7, 2017, which is a continuation of U.S. patent application Ser. No. 12/071,486, filed on Feb. 21, 2008, now U.S. Pat. No. 9,754,077, which claims the benefit of priority to U.S. Provisional Patent Application No. 60/902,490, filed on Feb. 22, 2007, the entireties of each of which are incorporated by reference herein.

US Referenced Citations (292)
Number Name Date Kind
3810102 Parks, III et al. May 1974 A
4173971 Karz Nov 1979 A
4428733 Kumar-Misir Jan 1984 A
4439242 Hadden Mar 1984 A
4712562 Ohayon et al. Dec 1987 A
4731726 Allen, III Mar 1988 A
4803625 Fu et al. Feb 1989 A
4835372 Gombrich et al. May 1989 A
4838275 Lee Jun 1989 A
4960118 Pennock Oct 1990 A
5019974 Beckers May 1991 A
5036462 Kaufman et al. Jul 1991 A
5036852 Leishman Aug 1991 A
5077476 Rosenthal Dec 1991 A
5307263 Brown Apr 1994 A
5339921 Fujimoto Sep 1994 A
5348008 Bornn et al. Sep 1994 A
5377258 Bro Dec 1994 A
5390238 Kirk et al. Feb 1995 A
5437278 Wilk Aug 1995 A
5437634 Amano Aug 1995 A
5465082 Chaco Nov 1995 A
5544661 Davis et al. Aug 1996 A
5569212 Brown Oct 1996 A
5596994 Bro Jan 1997 A
5601435 Quy Feb 1997 A
5626144 Tacklind et al. May 1997 A
5628209 Brown May 1997 A
5692906 Corder Dec 1997 A
5704922 Brown Jan 1998 A
5720733 Brown Feb 1998 A
5722418 Brown Mar 1998 A
5730654 Brown Mar 1998 A
5772586 Heinonen et al. Jun 1998 A
5782814 Brown et al. Jul 1998 A
5792117 Brown Aug 1998 A
5794219 Brown Aug 1998 A
5822715 Worthington et al. Oct 1998 A
5828943 Brown Oct 1998 A
5832448 Brown Nov 1998 A
5879163 Brown et al. Mar 1999 A
5887133 Brown et al. Mar 1999 A
5897493 Brown Apr 1999 A
5899855 Brown May 1999 A
5902234 Webb May 1999 A
5913310 Brown Jun 1999 A
5918603 Brown Jul 1999 A
5933136 Brown Aug 1999 A
5940801 Brown Aug 1999 A
5941829 Saltzstein Aug 1999 A
5951300 Brown Sep 1999 A
5956501 Brown Sep 1999 A
5960403 Brown Sep 1999 A
5967975 Ridgeway Oct 1999 A
5977059 Khoo Nov 1999 A
5985559 Brown Nov 1999 A
5997476 Brown Dec 1999 A
6023686 Brown Feb 2000 A
6024699 Surwit et al. Feb 2000 A
6032119 Brown et al. Feb 2000 A
6068615 Brown et al. May 2000 A
6101478 Brown Aug 2000 A
6110148 Brown et al. Aug 2000 A
6113578 Brown Sep 2000 A
6144837 Quy Nov 2000 A
6151586 Brown Nov 2000 A
6161095 Brown Dec 2000 A
6167362 Brown et al. Dec 2000 A
6167386 Brown Dec 2000 A
6168563 Brown Jan 2001 B1
6186145 Brown Feb 2001 B1
6196970 Brown Mar 2001 B1
6210272 Brown Apr 2001 B1
6231519 Blants et al. May 2001 B1
6233539 Brown May 2001 B1
6234964 Iliff et al. May 2001 B1
6240393 Brown May 2001 B1
6246992 Brown Jun 2001 B1
6248065 Brown Jun 2001 B1
6260022 Brown Jul 2001 B1
6270455 Brown Aug 2001 B1
6302844 Walker et al. Oct 2001 B1
6330426 Brown et al. Dec 2001 B2
6334778 Brown Jan 2002 B1
6352523 Brown et al. Mar 2002 B1
6368273 Brown Apr 2002 B1
6375469 Brown Apr 2002 B1
6375614 Braun et al. Apr 2002 B1
6379301 Worthington et al. Apr 2002 B1
6381577 Brown Apr 2002 B1
6402691 Peddicord et al. Jun 2002 B1
6409660 Sjogvist et al. Jun 2002 B1
6416471 Kumar et al. Jul 2002 B1
6418346 Nelson et al. Jul 2002 B1
6454705 Cosentino et al. Sep 2002 B1
6482156 Iliff et al. Nov 2002 B2
6565509 Say et al. May 2003 B1
6579231 Phipps Jun 2003 B1
6510010 Sjogvist et al. Aug 2003 B1
6602191 Quy Aug 2003 B2
6610012 Mault et al. Aug 2003 B2
6645142 Braig et al. Nov 2003 B2
6669631 Norris et al. Dec 2003 B2
6675030 Ciurczak et al. Jan 2004 B2
6694177 Eggers et al. Feb 2004 B2
6699188 Wessel Mar 2004 B2
6723045 Cosentino et al. Apr 2004 B2
6723046 Lichtenstein et al. Apr 2004 B2
6783492 Dominguez et al. Aug 2004 B2
6804558 Haller et al. Oct 2004 B2
6820057 Loch et al. Nov 2004 B1
6840904 Goldberg Jan 2005 B2
6849045 Iliff Feb 2005 B2
6885544 Austin Mar 2005 B2
6875174 Braun et al. Apr 2005 B2
6891936 Kai et al. May 2005 B2
6893396 Schulze et al. May 2005 B2
6920360 Lee et al. Jul 2005 B2
6936007 Quy Aug 2005 B2
6955646 Christ et al. Oct 2005 B2
6968375 Brown et al. Nov 2005 B1
6976958 Quy Dec 2005 B2
6985762 Brashears et al. Jan 2006 B2
7077806 Ackermann et al. Jul 2006 B2
7104955 Bardy Sep 2006 B2
7130396 Rogers et al. Oct 2006 B2
7156808 Quy Jan 2007 B2
7156809 Quy Jan 2007 B2
7167818 Brown Jan 2007 B2
7188151 Kumar et al. Mar 2007 B2
7223235 Brown May 2007 B2
7223236 Brown May 2007 B2
7252636 Brown Aug 2007 B2
7258666 Brown Aug 2007 B2
7260480 Brown et al. Aug 2007 B1
7264591 Brown Sep 2007 B2
7277867 Brown et al. Oct 2007 B1
7297109 Brown Nov 2007 B2
7305348 Brown Dec 2007 B1
7310668 Brown Dec 2007 B2
7320030 Brown Jan 2008 B2
7321920 Washburn Jan 2008 B2
7392167 Brown Jan 2008 B2
7340503 Washburn Mar 2008 B2
7353258 Washburn Apr 2008 B2
7399276 Brown et al. Jul 2008 B1
20010011224 Brown Aug 2001 A1
20010016310 Brown et al. Aug 2001 A1
20010039373 Cunningham et al. Nov 2001 A1
20010047252 Brown Nov 2001 A1
20010049096 Brown Dec 2001 A1
20020016719 Nemeth et al. Feb 2002 A1
20020019748 Brown Feb 2002 A1
20020026223 Riff et al. Feb 2002 A1
20020039373 Ishimaru Apr 2002 A1
20020052539 Haller et al. May 2002 A1
20020111541 Bibl et al. Aug 2002 A1
20020120310 Linden et al. Aug 2002 A1
20020128866 Goetzke Sep 2002 A1
20020133377 Brown Sep 2002 A1
20030000088 Korth et al. Jan 2003 A1
20030036683 Kehr et al. Feb 2003 A1
20030072424 Evans et al. Apr 2003 A1
20030088290 Spinelli et al. May 2003 A1
20030163351 Brown et al. Aug 2003 A1
20030166994 Ooshima et al. Sep 2003 A1
20030208113 Mault Nov 2003 A1
20030212579 Brown et al. Nov 2003 A1
20030229514 Brown Dec 2003 A2
20040019259 Brown et al. Jan 2004 A1
20040044272 Moerman et al. Mar 2004 A1
20040054263 Moerman et al. Mar 2004 A1
20040102683 Khanuja et al. May 2004 A1
20040102685 Cosentino et al. May 2004 A1
20040106855 Brown Jun 2004 A1
20040107116 Brown Jun 2004 A1
20040117207 Brown Jun 2004 A1
20040117208 Brown Jun 2004 A1
20040117209 Brown Jun 2004 A1
20040117210 Brown Jun 2004 A1
20040122297 Stahmann et al. Jun 2004 A1
20040133080 Mazar et al. Jul 2004 A1
20040176666 Chait Sep 2004 A1
20040215492 Choi Oct 2004 A1
20040236189 Hawthorne et al. Nov 2004 A1
20040236199 Hawthorne et al. Nov 2004 A1
20040249250 Mcgee et al. Dec 2004 A1
20050003470 Nelson et al. Jan 2005 A1
20050010087 Banet et al. Jan 2005 A1
20050059895 Brown Mar 2005 A1
20050060194 Brown Mar 2005 A1
20050065815 Mazar et al. Mar 2005 A1
20050075542 Goldreich Apr 2005 A1
20050080322 Korman Apr 2005 A1
20050080652 Brown Apr 2005 A1
20050086083 Brown Apr 2005 A1
20050113655 Hull May 2005 A1
20050197553 Cooper Sep 2005 A1
20050216199 Banet Sep 2005 A1
20050228883 Brown Oct 2005 A1
20050234307 Heinonen et al. Oct 2005 A1
20050235060 Brown Oct 2005 A1
20050240111 Chung Oct 2005 A1
20050273509 Brown Dec 2005 A1
20050283385 Hunkeler Dec 2005 A1
20060004611 Brown Jan 2006 A1
20060009684 Kim Jan 2006 A1
20060009697 Banet et al. Jan 2006 A1
20060009705 Brown Jan 2006 A1
20060009706 Brown Jan 2006 A1
20060010014 Brown Jan 2006 A1
20060017563 Rosenfeld et al. Jan 2006 A1
20060022834 Rosenfeld et al. Feb 2006 A1
20060025657 Rosenfeld et al. Feb 2006 A1
20060036134 Tarassenko et al. Feb 2006 A1
20060036619 Fuerst Feb 2006 A1
20060074338 Greenwald et al. Apr 2006 A1
20060080152 Brown Apr 2006 A1
20060089542 Sands Apr 2006 A1
20060089969 Brown Apr 2006 A1
20060100910 Brown May 2006 A1
20060129432 Choi et al. Jun 2006 A1
20060142648 Banet et al. Jun 2006 A1
20060155582 Brown Jul 2006 A1
20060167345 Vespasiani Jul 2006 A1
20060167346 Sarel Jul 2006 A1
20060173260 Gaoni et al. Aug 2006 A1
20060173715 Wang Aug 2006 A1
20060178914 Brown Aug 2006 A1
20060189853 Brown Aug 2006 A1
20060212316 Jackson et al. Sep 2006 A1
20060234202 Brown Oct 2006 A1
20060235722 Brown Oct 2006 A1
20060241975 Brown Oct 2006 A1
20060247951 Brown Nov 2006 A1
20060252089 Brown Nov 2006 A1
20060253296 Liisberg et al. Nov 2006 A1
20060253303 Brown Nov 2006 A1
20060253574 Brown Nov 2006 A1
20060253576 Brown Nov 2006 A1
20060259201 Brown Nov 2006 A1
20060259332 Brown Nov 2006 A1
20060271214 Brown Nov 2006 A1
20060271404 Brown Nov 2006 A1
20060285660 Brown Dec 2006 A1
20060285736 Brown Dec 2006 A1
20060287883 Turgiss Dec 2006 A1
20060287889 Brown Dec 2006 A1
20060287931 Brown Dec 2006 A1
20060293571 Bao et al. Dec 2006 A1
20060293607 Alt et al. Dec 2006 A1
20060294233 Brown Dec 2006 A1
20070010719 Huster et al. Jan 2007 A1
20070011320 Brown Jan 2007 A1
20070016445 Brown Jan 2007 A1
20070016446 Brown Jan 2007 A1
20070016447 Brown Jan 2007 A1
20070018448 Brown Jan 2007 A1
20070021984 Brown Jan 2007 A1
20070032997 Brown Feb 2007 A1
20070048691 Brown Mar 2007 A1
20070055486 Brown Mar 2007 A1
20070060796 Kim Mar 2007 A1
20070061167 Brown Mar 2007 A1
20070067251 Brown Mar 2007 A1
20070068539 Hall et al. Mar 2007 A1
20070076681 Brown Apr 2007 A1
20070094049 Brown Apr 2007 A1
20070094353 Brown Apr 2007 A1
20070100665 Brown May 2007 A1
20070100932 Brown May 2007 A1
20070100934 Brown May 2007 A1
20070118348 Brown May 2007 A1
20070118403 Brown May 2007 A1
20070118404 Brown May 2007 A1
20070118588 Brown May 2007 A1
20070118589 Brown May 2007 A1
20070124179 Brown May 2007 A1
20070124466 Brown May 2007 A1
20070135688 Brown Jun 2007 A1
20070156457 Brown Jul 2007 A1
20070156893 Brown Jul 2007 A1
20070168226 Brown Jul 2007 A1
20070168242 Brown Jul 2007 A1
20070168504 Brown Jul 2007 A1
20070179352 Randlov et al. Aug 2007 A1
20070212671 Brown Sep 2007 A1
20070213603 Brown Sep 2007 A1
20070213604 Brown Sep 2007 A1
20070213605 Brown Sep 2007 A1
20070213608 Brown Sep 2007 A1
20070287895 Brown Dec 2007 A1
Foreign Referenced Citations (1)
Number Date Country
WO 9963462 Dec 1999 WO
Non-Patent Literature Citations (8)
Entry
Montani et al., “Protocol-based Reasoning in Diabetic Patient Management,” International Journal of Medical Informatics, Elsevier Scientific Publishers, Shannon, IR, vol. 53, No. 1, Jan. 1, 1999, pp. 61-77.
Lehmann et al., “AIDA2: : A Mk. II Automated Insulin Dosage Advisor,” Journal of Biomedical Engineering, Butterworth, Guildford, GB, vol. 15, No. 3, May 1, 1993, pp. 201-211.
Deutsch T et al., “Utopia: A Consultation System for Visit-by-Visit Diabetes Management,” Medical Informatica, Taylor and Francis, Basingstoke, GB, vol. 21, No. 4, Oct. 1, 1996, pp. 345-358.
Steil G. M. et al., “Modeling Insulin Action for Development of a Closed-Loop Artificial Pancreas,” Diabetes Technology and Therapeutics, Mary Ann Liebert, Larchmont, NY, vol. 7, No. 1, Feb. 1, 2005, pp. 94-109.
Boutayeb A. et al., “A critical reviewk of Mathematical Models and Data Used in Diabetology,” Biomedical Engineering Online, Biomed Central Ltd., London, England, vol. 5, No. 1, Jun. 19, 2006.
Rune V. Overgaard et al., “Mathematical Beta Cell Model for Insulin Secretion Following IVGIT and OGTT,” Annals of Biomedical Engineering, Kluwer Academic Publishers-Plenum Publishers, NE, vol. 34, No. 8, Jul. 13, 2006.
Minor J. M. et al., “Analysis of Clinical Data Using Neural Nets,” Journal of Biopharmaceutical Statistics, Mar. 1996, vol. 6, No. 1, Mar. 1996.
Written Opinion of the International Searching Authority issued by the European Patent Office dated Jul. 17, 2008.
Related Publications (1)
Number Date Country
20190180855 A1 Jun 2019 US
Provisional Applications (1)
Number Date Country
60902490 Feb 2007 US
Continuations (2)
Number Date Country
Parent 15670551 Aug 2017 US
Child 16186996 US
Parent 12071486 Feb 2008 US
Child 15670551 US